Caxton Associates LP Buys Shares of 8,485 BioNTech SE (NASDAQ:BNTX)

Caxton Associates LP purchased a new position in shares of BioNTech SE (NASDAQ:BNTX - Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 8,485 shares of the company's stock, valued at approximately $682,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of BNTX. GAMMA Investing LLC grew its stake in shares of BioNTech by 121.0% in the first quarter. GAMMA Investing LLC now owns 274 shares of the company's stock worth $25,000 after acquiring an additional 150 shares in the last quarter. Covestor Ltd increased its stake in shares of BioNTech by 47.2% during the first quarter. Covestor Ltd now owns 415 shares of the company's stock worth $38,000 after buying an additional 133 shares during the period. EverSource Wealth Advisors LLC raised its holdings in BioNTech by 106.3% in the first quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company's stock valued at $43,000 after acquiring an additional 252 shares in the last quarter. Crewe Advisors LLC acquired a new position in BioNTech during the 1st quarter worth approximately $75,000. Finally, American National Bank acquired a new stake in shares of BioNTech in the 1st quarter valued at $81,000. 15.52% of the stock is owned by institutional investors and hedge funds.

BioNTech Stock Up 1.3 %

Shares of NASDAQ BNTX opened at $119.20 on Friday. The stock has a market capitalization of $28.34 billion, a price-to-earnings ratio of 235.28 and a beta of 0.23. BioNTech SE has a 52 week low of $76.53 and a 52 week high of $131.49. The firm has a 50-day moving average price of $93.23 and a 200 day moving average price of $91.33. The company has a quick ratio of 7.40, a current ratio of 7.54 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its quarterly earnings results on Monday, August 5th. The company reported ($3.36) earnings per share for the quarter, missing analysts' consensus estimates of ($2.02) by ($1.34). BioNTech had a negative return on equity of 2.54% and a negative net margin of 18.69%. The firm had revenue of $128.70 million during the quarter, compared to analyst estimates of $134.98 million. During the same quarter in the prior year, the company earned ($0.86) EPS. The business's revenue was down 23.3% on a year-over-year basis. Equities research analysts anticipate that BioNTech SE will post -2.87 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. Hsbc Global Res raised BioNTech from a "hold" rating to a "strong-buy" rating in a report on Friday, August 2nd. HSBC upgraded BioNTech from a "hold" rating to a "buy" rating in a research report on Friday, August 2nd. Bank of America boosted their price objective on BioNTech from $125.00 to $150.00 and gave the company a "buy" rating in a research note on Monday, September 16th. TD Cowen lowered their target price on shares of BioNTech from $98.00 to $85.00 and set a "hold" rating on the stock in a research report on Tuesday, August 6th. Finally, UBS Group increased their price target on shares of BioNTech from $97.00 to $131.00 and gave the stock a "neutral" rating in a research note on Wednesday, September 18th. Five equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, BioNTech has an average rating of "Moderate Buy" and an average price target of $127.15.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.